Abstract
Cold atmospheric plasma-activated hydrogel (PAH) exhibits excellent loading and slow-release capacity for plasma-generated reactive species. In this study, plasma-activated pluronic F127 hydrogel (PAH-PF127) was obtained using surface dielectric barrier discharge (SDBD), and the anticancer effects of PAH-F127 synergies with the clinical drug paclitaxel (PTX) were investigated. The results indicated that PAH-PF127 could load plasma-generated long-lived reactive species efficiently, and in vitro research revealed that PAH-PF127 exerts significant anticancer effects by inducing intracellular oxidative stress, and synergies with 50 μg/mL (low-dose) PTX could easily replace 200 μg/mL (high-dose) PTX alone. These results suggested that PAH-PF127 has the potential to address the toxic side effects of high-dose drugs and expand the application of plasma technology in anticancer treatment.
| Original language | English |
|---|---|
| Article number | 2400167 |
| Journal | Plasma Processes and Polymers |
| Volume | 22 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2025 |
Keywords
- anticancer effect
- cold atmospheric plasma
- plasma-activated hydrogel
- reactive oxygen and nitrogen species
Fingerprint
Dive into the research topics of 'Plasma-Activated Hydrogel Synergies With Paclitaxel to Enhance the Anticancer Efficacy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver